Flat-fixed dosing versus body surface area-based dosing of anticancer drugs: There is a difference

Oncologist

Volumn 12, Issue 8, 2007, Pages 924-926

  Hempel, Georg ^a,b   Boos, Joachim ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Klinik und Poliklinik fur Kinder und Jugendmedizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; DOCETAXEL; IRINOTECAN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR;

AGE DISTRIBUTION; AREA UNDER THE CURVE; BODY HEIGHT; BODY MASS; BODY SURFACE; BODY WEIGHT; DOSE CALCULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG MONITORING; GLOMERULUS FILTRATION RATE; HUMAN; INDIVIDUALITY; LEUKEMIA; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; NEUROBLASTOMA; NOTE; OTOTOXICITY; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY SURFACE AREA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE;

EID: 34548435653     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-8-924     Document Type: Note

References (22)

1. Mathijssen RHJ, de Jong FA, Loos WJ et al. Flat-fixed versus body surface area-based dosing of anticancer drugs in adults: Does it make a difference? The Oncologist 2007;12:913-923.
2. Shaked Y, Bocci G, Munoz R et al. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 2005;5:551-559.
3. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18:853-856.
4. Crawford JD, Terry ME, Rourke GM. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 1950;5:783-790.
5. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: The good, the bad and body-surface area. Eur J Cancer 2002;38:1677-1684.
6. Bleyzac N, Souillet G, Magron P et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001;28:743-751.
7. Gurney H. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-2611.
8. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19:171-177.
9. Baker SD, Verweij J, Rowinsky EK et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-1888.
10. Smorenburg CH, Sparreboom A, Bontenbal M et al. Randomized crossover evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003;21:197-202.
11. Rodman JH, Relling MV, Stewart CF et al. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 1993;20:18-29.
12. Newell DR, Pearson AD, Balmanno K et al. Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol 1993;11:2314-2323.
13. Calvert AH, Egorin MJ. Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002;38:11-16.
14. de Jongh FE, Verweij J, Loos WJ et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19:3733-3739.
15. de Jongh FE, Gallo JM, Shen M et al. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004;54:105-112.
16. Loos WJ, de Jongh FE, Sparreboom A et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 2006;24:1499-1506.
17. Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004;57:756-763.
18. Peng B, English MW, Boddy AV et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer 1997;33:1823-1828.
19. Goodisman J, Souid AK. Constancy in integrated cisplatin plasma concentrations among pediatric patients. J Clin Pharmacol 2006;46:443-448.
20. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: Clinical perspectives on the utility of genotyping. Pharmacogenomics 2006;7:1211-1221.
21. Yamamoto N, Tamura T, Murakami H et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005;23:1061-1069.
22. Chatelut E, Boddy AV, Peng B et al. Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 1996;59:436-443.